Indications
Improvement of liver fibrosis and resolution of steatohepatitis in adult patients with significant liver fibrosis due to nonalcoholic steatohepatitis (NASH)
Composition
- Active substance
- obeticholic acid
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zektayos - Hepjuvo
- Active substance
- obeticholic acid
- ATC code
- A05AA04
- Therapeutic area
- Fatty Liver
- Marketing authorisation holder
- Advanz Pharma Limited
- Status
- Application withdrawn
- EMA product number